Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies
Authors' conclusion
Oral semaglutide 7 and 14 mg resulted in greater time spent with HbA1c less than 7.0%, and a greater likelihood of achieving and maintaining HbA1c less than 7.0% versus oral comparators.
Study context
- Population
- Participants with T2D randomized in the PIONEER trialsall randomized participants
- Participants
- 1,880 vs 1,412
- Comparison
- Oral semaglutide 7 mg vs sitagliptin 100 mg; oral semaglutide 14 mg vs empagliflozin 25 mg, sitagliptin 100 mg or subcutaneous liraglutide 1.8 mg
- Oral semaglutiden = 1,880
- Comparatorsn = 1,412reference
- Primary endpoint
- Duration of time with HbA1c <7.0%, calculated using an HbA1c time curve
Methodological detailson-treatment data without rescue medication
- On-treatment data without rescue medication
Primary result
As reported in the abstract
Mean duration of time with HbA1c <7.0%
Greater with oral semaglutide 7 mg vs sitagliptin in PIONEER 3
27 vs. 22 weeks
Greater with oral semaglutide 14 mg vs empagliflozin and sitagliptin
27-34 vs. 19 vs. 22 weeks
Further findings
Achieved and maintained HbA1c <7.0% for >75% of the trial
- Greater proportion with oral semaglutide 14 mg vs oral comparators
Achieving HbA1c <7.0% · weeks 24/26 and 52/78
- Odds significantly greater with oral semaglutide 14 mg vs oral comparators or subcutaneous liraglutide, and with oral semaglutide 7 mg vs sitagliptin
Original publication
Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies. Diabetes Obes Metab. Published 7 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →